Evoke Pharma stock enters a cash merger transaction

Evoke Pharma (ISIN US30053E1055) is tied to a cash merger transaction in which shareholders are slated to receive USD 11.00 per share, according to Robinhood. The company develops Gimoti, a prescription treatment for symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes, as Robinhood describes.

Cash terms define the transaction

The USD 11.00 per share consideration is the clearest numerical reference for the corporate action. The transaction therefore centers on cash conversion rather than a new operating forecast for Gimoti or a new product launch.

Robinhood identifies Evoke Pharma as a pharmaceutical company focused on gastrointestinal disorders and lists four employees, while the company profile gives 2007 as the founding year. Those figures describe a small operating structure around a single marketed product.

Historical figures show the operating base

For historical context, Rallies reported trailing-twelve-month revenue of USD 14.42 million and net income of negative USD 5.23 million as of September 5, 2026. The same report listed EPS of negative USD 1.38, making profitability the central counterweight to the transaction's fixed cash consideration.

Rallies also reported an average analyst price target of USD 18.00 from 12 analysts against a USD 11.00 quote in its September 5, 2026 analysis. That difference amounts to 63.64 percent above the quoted value, but the historical estimate belongs to a period before the cash merger entry listed by Robinhood.

NASDAQ listing frames the security

NASDAQ identifies Evoke Pharma as NASDAQ: EVOK and reported a USD 11.00 previous close in its September 7, 2026 snapshot. Its profile also showed a 50-day moving average of USD 8.52 and a 200-day moving average of USD 5.04, placing the historical quote above both reference levels.

More news and analyses on Evoke Pharma stock